StockData
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Evaxion A/S

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026
$3.33+0.50 (+17.67%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Earnings

Quarterly results announced on Form 8-K, Item 2.02

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 20, 2026Before market open–$-0.01–
Q4 FY2025
Ended Dec 31, 2025
Mar 5, 2026During market hours–$-0.02–
Q2 FY2025
Ended Jun 30, 2025
Aug 14, 2025Before market open$37.00K$-0.02–
Q4 FY2024
Ended Dec 31, 2024
Apr 1, 2025Before market open$122.00K$-0.07–
Q2 FY2024
Ended Jun 30, 2024
Aug 14, 2024Before market open$154.00K$-0.12–
Q4 FY2023
Ended Dec 31, 2023
Mar 27, 2024Before market open$73.00K$-0.16–
Q2 FY2023
Ended Jun 30, 2023
Aug 17, 2023After market close–$-0.21–
Q4 FY2022
Ended Dec 31, 2022
Apr 27, 2023Before market open–$-0.29–

Company guidance

Outlook given with results on Mar 5, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
operational cash burn2026$14.00MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Evaxion A/S filed with the SEC